Clinical Trial Detail

NCT ID NCT01912963
Title Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Eribulin

Pertuzumab

Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST